Article

HTA Quarterly Spring 2024

In this edition, we continue our series on preparing for the introduction of European Union (EU) health technology assessment (HTA), consider how United States (U.S.) drug pricing negotiations under the Inflation Reduction Act (IRA) compare with those in countries with an established price negotiation framework, and assess the strengths and limitations of artificial intelligence (AI) tools for literature reviews.

It’s Just…So…Cool – Don’t miss your opportunity for JSC!

The implementing acts on Joint Scientific Consultation (JSC) and Joint Clinical Assessment (JCA) by the European Commission (EC) are eagerly awaited by the industry and national HTA authorities. What are current developments, and how can stakeholders prepare for the EU HTA during the interim period?
Awaiting the JCA implementing acts

Rating the robots: Artificial intelligence for literature reviews

So much scientific evidence, so little time. We assess the performance and capabilities of our newest team member: AI. 

Rating AI for Lit reviews

Apples to apples, or apples to oranges? Comparing the Inflation Reduction Act to drug-pricing programs in other countries

The IRA allows the federal government to negotiate U.S. drug prices for the first time. This article considers how the US system may evolve based on comparison with established price-negotiation processes in Canada, France, and Germany.
Advanced therapies week

Heard on the street

“Because AstraZeneca has no legitimate claim of entitlement to sell its drugs to the government at any price other than what the government is willing to pay, its due process claim fails as a matter of law.”

U.S. District Judge Colm Connolly wrote in his opinion regarding a lawsuit that challenged the constitutionality of the Inflation Reduction Act (IRA) in a federal court in Delaware, less than 3 weeks after a Texas judge tossed a similar lawsuit by industry lobbying group PhRMA.

Delaware court dismisses AstraZeneca suit challenging IRA

HTA by the numbers

100%

“I think one of the remarkable things about the presentations that I saw today at this conference was that literally 100% of the payers and providers who presented today mentioned AI as a prominent part of their strategy for 2024,” said Julie Yoo, general partner at Andreessen Horowitz, while moderating a conference panel discussion on AI.

JPM24: Top trends for payers, providers, and health tech companies to watch

Related resources

Article

Insights from Pharma 2025: Ready or not? Preparing for the EU HTA wave
Learn more

Webinar

How full pharmacovigilance outsourcing increases efficiency and accuracy
Learn more

Article

Cencora ThinkLive Cell and Gene Therapy Virtual Summit 2025
Learn more

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.